Nucleome names Bhavna Hunjan as chief business officer

UK biotech Nucleome Therapeutics has appointed Bhavna Hunjan as chief business officer, a move that strengthens its leadership as it advances its pipeline of antibody therapies for inflammatory diseases.

Ms Hunjan, who starts immediately, will oversee business development, strategic partnerships, and financing efforts. She joins from C4X Discovery where she played a central role in securing licensing deals and supporting capital raising. Her previous experience spans roles at Lehman Brothers, Nomura International, PwC, and Cancer Research UK.

The Oxford-based company is focused on decoding the non-coding regions of the human genome, aiming to discover novel, first-in-class therapies. Its approach combines proprietary laboratory techniques with machine learning to map disease biology, with early-stage programs now emerging from this platform.